<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742492</url>
  </required_header>
  <id_info>
    <org_study_id>FUNCTIONALTUNA1</org_study_id>
    <nct_id>NCT03742492</nct_id>
  </id_info>
  <brief_title>Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects</brief_title>
  <official_title>Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects on Cardiovascular Risk Markers, in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Health Technology and Services Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVA Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade do Porto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence has suggested that omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and
      docosahexaenoic acid (DHA), have an important role in promoting cardiovascular health.
      However, the currently available scientific literature describing the postprandial effects
      and bioavailability of these fatty acids, particularly when they are incorporated into high
      protein food item, like canned tuna, is far from conclusive.

      The aim of this study is to evaluate the acute bioavailability of EPA + DHA enriched canned
      tuna and its acute effects on cardiovascular risk markers, in healthy human volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial plasma triglycerides concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of triglycerides (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial plasma low-density lipoprotein (LDL) cholesterol concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of LDL cholesterol (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial plasma total cholesterol concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of total cholesterol (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial blood pressure</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of blood pressure (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma high-density lipoprotein (HDL) cholesterol concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of HDL cholesterol (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma eicosapentaenoic acid (EPA) concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of EPA (0, 2, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma docosahexaenoic acid (DHA) concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of DHA (0, 2, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma blood glucose concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of blood glucose (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma insulin concentrations</measure>
    <time_frame>Up to 5 hour post-meal.</time_frame>
    <description>Impact on the postprandial levels of insulin (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma Apolipoprotein B-48 (apoB-48) concentrations</measure>
    <time_frame>Up to 5 hours post-meal.</time_frame>
    <description>Impact on the postprandial levels of ApoB-48 (0, 1, 2, 3, 4, and 5 hours post-meal).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Canned tuna + fish oil (5 g EPA + DHA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meal containing canned tuna + fish oil (5 g EPA + DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canned tuna + soybean oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Meal containing canned tuna + soybean oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meal containing canned tuna + fish oil (5 g EPA + DHA)</intervention_name>
    <description>Meal containing canned tuna + fish oil (5 g EPA + DHA)</description>
    <arm_group_label>Canned tuna + fish oil (5 g EPA + DHA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meal containing canned tuna + soybean oil</intervention_name>
    <description>Meal containing canned tuna + soybean oil</description>
    <arm_group_label>Canned tuna + soybean oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men or women

          -  Age 18 - 59 years

          -  Willing to maintain usual diet and physical activity patterns

          -  Willing to comply with study protocol and procedures

          -  Willing to provide written informed consent

        Exclusion Criteria:

          -  Pregnant, breastfeeding or planning to become pregnant within the study period

          -  Subjects with current or previous cardiovascular disease (ischemic cardiovascular
             disease, angina stable or unstable; myocardial infarction, stroke or symptomatic
             peripheral arteriosclerosis)

          -  Subjects with liver or kidney diseases or cancer

          -  Diabetes mellitus (fasting glycemia&gt; 126 mg / dL)

          -  Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood
             pressure ≥100 mmHg)

          -  Subjects with history of drug, alcohol or other substances abuse, or other factors
             limiting their ability to cooperate during the study

          -  Subjetcs with gastrointestinal disorder or under prescription for medication affecting
             gastrointestinal function or absorption of nutrients

          -  Known allergy (or sensitivity) to omega-3 fatty acids, fish (tuna), crustaceans,
             lactose or any meal ingredient

          -  With antihypertensive therapy

          -  Health condition that prevents compliance with study requirements

          -  Subjects under prescription for medication for digestive symptoms such as
             anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries

          -  Subjects under prescription of anticoagulant drugs

          -  Dietary patterns or supplement use that could interfere with study evaluations

          -  Subjects not willing to avoid the consumption of fish oil or food supplements,
             including fatty acids, during the study (except as indicated in the study protocol)

          -  Use of antibiotics in the last 4 weeks and laxatives in the last 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Conceição Calhau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CINTESIS, NOVA Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luís Azevedo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CINTESIS, Faculty of Medicine of the University of Porto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CINTESIS - Faculty of Medicine of the University of Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200-450</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>https://www.researchgate.net/project/FUNCTIONALTUNA</url>
    <description>Project FUNCTIONALTUNA financed by COMPETE2020 (POCI-01-0247-FEDER-003466)</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Eicosapentaenoic acid (EPA)</keyword>
  <keyword>Docosahexaenoic acid (DHA)</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Lipid absorption</keyword>
  <keyword>Canned tuna</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

